In brief Moderna (MRNA) jumped ~131% Wednesday after the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda hit its RFS and DMFS endpoints in resected melanoma. Intismeran autogene is a personalized mRNA neoantigen therapy built from each patient’s tumor mutations, paired with Merck’s Keytruda immunotherapy. Traders shorting Moderna faced ~$4.8B in mark-to-market losses as the stock doubled; short interest sat at 13.5% of free float. Moderna’s personalized mRNA cancer shot cleared its first Phase 3 readout, and the market reacted like it had won more than a trial.Shares of Moderna, which trades as MRNA, surged about 131% on Wednesday,…

Centrifuge has added Symbiotic’s liquidity network across three tokenized funds that represent about $1.6 billion in assets under management, giving eligible holders another route to exchange their positions for USDC.The integration covers Janus Henderson’s JAAA, an AAA-rated collateralized loan obligation strategy, JTRSY, a short-duration US Treasury strategy and New York Life Investment Management’s HYB, a US high-yield corporate bond strategy.Symbiotic’s Liquid Lane uses an onchain request-for-quote (RFQ) marketplace where market makers can tap liquidity from vaults to fill redemption requests. Market makers can then redeem the acquired fund tokens through the issuer or sell them through another RFQ transaction.The arrangement…

AI & Crypto

Read More

Politics

Don't Miss!